1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Castleman Disease: new trials by email Literature Review of Castleman Disease trials Research Report on Castleman Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease Ruxolitinib - Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease | Phase 2 | Recruiting | University of Pennsylvania | 14 | 2025-12-18 | 2026-04-22 |
| Nintedanib Treatment in Unicentric Castleman Disease Nintedanib - Castleman Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 13 | 2024-11-01 | 2024-10-15 |
| Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Sirolimus - Castleman Disease, Castleman's Disease, Multicentric | Phase 2 | Active not recruiting | University of Pennsylvania | 7 | 2019-09-25 | 2026-08-20 |
| Tocilizumab for KSHV-Associated Multicentric Castleman Disease Zidovudine, Tocilizumab, Valganciclovir (VGC) - Castleman Disease, Multicentric Castleman Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-09-13 | 2020-10-27 |
| Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Rituximab - HIV Infections, Giant Lymph Node Hyperplasia | Phase 2 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 25 | 2003-05-01 | 2007-01-12 |
Multi-centric Castleman's Disease (2) · Sarcoma, Kaposi (2) · Acquired Immunodeficiency Syndrome (1) · HIV Infections (1) · Macular dystrophy, corneal type 1 (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Blood-Borne Infections (2) · Communicable Diseases (2) · DNA Virus Infections (2) · Genital Diseases (2) · Herpesviridae Infections (2) · Immunologic Deficiency Syndromes (2) · Infections (2) · Lentivirus Infections (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Rituximab (1) · Sirolimus (1) · Valganciclovir (1) · Zidovudine (1) · nintedanib (1) · ruxolitinib (1) · tocilizumab (1)
University of Pennsylvania (2) · Assistance Publique - Hôpitaux de Paris (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · National Cancer Institute (NCI) (1)
United States (3)
Joshua Brandstadter, MD, PhD, MSc (2) · Eric Oksenhendler, M.D. (1) · Robert Yarchoan, M.D. (1)